Will renaming PCOS help women get diagnosed? - What in the World podcast, BBC World Service

Key Concepts

• PMOS (Polyendocrine Metabolic Ovarian Syndrome): The new, more accurate clinical name for the condition formerly known as PCOS.
• Androgen Levels: Male hormones that are typically elevated in individuals with PMOS, contributing to physical symptoms.
• Insulin Resistance: A metabolic state where the body struggles to process sugar, leading to increased insulin production, which in turn triggers the ovaries to produce excess testosterone.
• Hirsutism: The growth of excess facial or body hair, a common symptom of PMOS.
• Metabolic Syndrome: A cluster of conditions (including insulin resistance) that occur together, increasing the risk of heart disease, stroke, and diabetes.
• Medical Coding: The system used by insurance companies and healthcare providers to classify diseases; changing the classification from "ovarian" to "metabolic/endocrine" is critical for insurance coverage and research funding.

---

1. The Shift from PCOS to PMOS

The condition previously known as Polycystic Ovary Syndrome (PCOS) is being officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS).

• Historical Inaccuracy: Professor Helena Teede explains that the original name was based on a 19th-century misinterpretation where surgeons observed "lumpy" ovaries and incorrectly labeled them as cysts.
• Reclassification: The new name moves the condition out of the narrow category of a "reproductive/ovarian disorder" and into a broader "metabolic and endocrine" classification.
• Strategic Importance: This reclassification is intended to break the "paralysis" in research funding. By moving away from the "cyst" label, the medical community aims to secure more resources for studying the systemic, whole-body impacts of the syndrome.

2. Symptoms and Diagnostic Challenges

PMOS is a complex, multi-faceted condition that affects approximately one in ten women of reproductive age, yet up to 70% of cases remain undiagnosed.

• Physical Symptoms: Hirsutism (excess facial/body hair), irregular or absent periods, acne, weight gain, bloating, skin tags, dark patches of skin, and sleep apnea.
• Psychological Impact: Patients report significant struggles with body image, femininity, anxiety, depression, and chronic fatigue.
• Diagnostic Barriers:
  • Normalization: In many regions, such as sub-Saharan Africa, period pain and irregularities are often normalized or stigmatized, preventing women from seeking medical help.
  • Narrow Focus: Historically, doctors relied heavily on ultrasounds to find cysts. Because not all patients present with cysts, many were misdiagnosed or dismissed.
  • Insurance/Coding: In the U.S., the "ovarian" label often limits insurance coverage to reproductive health, excluding the metabolic and systemic treatments patients actually need.

3. Pathophysiology: The Role of Insulin

The video highlights that PMOS is fundamentally a metabolic issue.

• The Mechanism: The pancreas produces insulin to process blood sugar. In PMOS patients, the body often becomes insulin-resistant. The pancreas compensates by producing more insulin, which signals the ovaries to produce excess testosterone (androgens).
• Management: While there is no known "cure," symptoms can be managed by addressing insulin resistance. This often involves dietary adjustments (e.g., low-carb, high-fat diets), though experts emphasize that there is no "one-size-fits-all" approach and patients should consult a GP or dietitian.

4. Patient Experiences and Real-World Applications

• Chelle (Florida, USA): Reported symptoms starting at age 11–12. She faced a decade of "pushback" from doctors who only offered birth control or metformin without a formal diagnosis or comprehensive care plan. She notes that the name change to PMOS is vital for insurance coverage in the U.S.
• Jenef (UK): Experienced the social stigma of facial hair at a young age. She emphasizes the need for more open, hopeful conversations about the condition to reduce the feeling of isolation.
• Treatment Reality: Both patients noted that finding effective treatments is a "trial and error" process. While some use IUDs for cycle management, they remain frustrated by the lack of holistic solutions.

5. Synthesis and Conclusion

The transition from PCOS to PMOS represents a paradigm shift in women's health. By moving away from the inaccurate "ovarian cyst" label, the medical community is acknowledging that this is a systemic metabolic and endocrine disorder. The primary takeaways are:

1. Awareness: The name change is a tool to improve global understanding and reduce the stigma that prevents early diagnosis.
2. Systemic Care: Effective management requires looking beyond the ovaries to address insulin resistance, metabolic health, and mental well-being.
3. Research Advocacy: The reclassification is a necessary step to unlock research funding and improve medical coding, which will ultimately lead to better insurance coverage and more effective, evidence-based treatments for patients.